IRLAB publishes the annual report for 2019
IRLAB announced today that the company’s annual report for fiscal year 2019, in Swedish, is published and available on the company’s website.
"We now have two drug candidates with new mechanisms of action that have delivered very positive results in Phase IIa studies for Parkinson’s; This confirms the power of innovation in our research platform ISP. We are now entering the “develop for launch” phase with mesdopetam and IRL752 and continues the development of our preclinical projects toward Phase I studies," says Nicholas Waters, CEO.
IRLAB’s annual report for 2019, in Swedish, is attached to this press release and is also available as a downloadable PDF on IRLAB's website, www.irlab.se/investor-relations/financial-reports/.